1. Long-term Outcomes of Cervical Adenocarcinoma Treated With Concurrent Chemoradiotherapy Using Paclitaxel and Cisplatin.
- Author
-
YOSHIHISA ARAKAKI, TAKURO ARIGA, JOICHI HEIANNA, YUKO SHIMOJI, TADAHARU NAKASONE, YUSUKE TAIRA, TOMOKO NAKAMOTO, TAKUMA OOYAMA, WATARU KUDAKA, ITOMI KANESHIMA, KUMIKO NISHIHIRA, KEIKO MEKARU, and YOICHI AOKI
- Subjects
CHEMORADIOTHERAPY ,ADENOCARCINOMA ,CANCER treatment ,PACLITAXEL ,CISPLATIN ,RADIOTHERAPY ,RADIOISOTOPE brachytherapy - Abstract
Background/Aim: We retrospectively analyzed the locally advanced adenocarcinoma (AC)/adenosquamous carcinoma (ASC) of the uterine cervix treated with concurrent chemoradiotherapy using cisplatin plus paclitaxel (TP-CCRT). Patients and Methods: Thirty patients with stage IB–IVA AC/ASC were treated with whole pelvis external beam radiotherapy. A high-dose-rate intracavitary brachytherapy was delivered once per week at a fractional dose of 6 Gy. For TP-CCRT, the patients received cisplatin and paclitaxel. Results: A complete response was achieved in 17 patients (77.3%) in the TP-CCRT group and 4 patients (50.0%) in the P-CCRT group. The 5-year OS rate in the TP-CCRT and P-CCRT groups was 74.2% and 25.0% (p=0.0094), the central DFS rate was 58.0% and 12.5% (p=0.0267), and the distant DFS rate was 63.6% and 12.5% (p=0.0042), respectively. Conclusion: TP-CCRT achieves a considerably better disease control for AC of the cervix, leading to a better OS. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF